Melatonin and Parkinson Disease: Current Status and Future Perspectives for Molecular Mechanisms

Omid Reza Tamtaji, Russel J. Reiter, Reza Alipoor, Ehsan Dadgostar, Ebrahim Kouchaki, Zatollah Asemi

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

Parkinson disease (PD) is a chronic and neurodegenerative disease with motor and nonmotor symptoms. Multiple pathways are involved in the pathophysiology of PD, including apoptosis, autophagy, oxidative stress, inflammation, α-synuclein aggregation, and changes in the neurotransmitters. Preclinical and clinical studies have shown that melatonin supplementation is an appropriate therapy for PD. Administration of melatonin leads to inhibition of some pathways related to apoptosis, autophagy, oxidative stress, inflammation, α-synuclein aggregation, and dopamine loss in PD. In addition, melatonin improves some nonmotor symptom in patients with PD. Limited studies, however, have evaluated the role of melatonin on molecular mechanisms and clinical symptoms in PD. This review summarizes what is known regarding the impact of melatonin on PD in preclinical and clinical studies.

Original languageEnglish (US)
Pages (from-to)15-23
Number of pages9
JournalCellular and Molecular Neurobiology
Volume40
Issue number1
DOIs
StatePublished - Jan 1 2020

Keywords

  • Apoptosis
  • Autophagy
  • Melatonin
  • Oxidative stress
  • Parkinson disease

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Cell Biology

Fingerprint Dive into the research topics of 'Melatonin and Parkinson Disease: Current Status and Future Perspectives for Molecular Mechanisms'. Together they form a unique fingerprint.

  • Cite this